Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease triggered by damage to the central nervous system (CNS). This CNS damage is caused by the attack of autoreactive T cells against the myelin sheath. Genetic and environmental factors contribute to the development of MS, and the condition causes serious disabilities and exerts substantial health burdens. Although various disease-modifying agents have been developed, they have critical limitations; hence, effective interventions are required. In this context, cell transplantation therapy using mesenchymal stem cells (MSCs), hematopoietic stem cells, neural precursors, neural stem cells, and induced pluripotent stem cells is considered a feasible alternative therapeutic approach. MSCs are adult stem cells that differentiate into multiple lineages and exert immunomodulatory, neuroprotective, and neuroregenerative effects. Therefore, MSCs are considered a promising treatment option for MS owing to their ease of isolation and low immunogenicity. This review summarizes the potential therapeutic benefits of the latest MSC-based approaches for MS treatment in animal models and humans. Furthermore, the review discusses the immunological role of MSCs and future directions for their applications.
No takes yet. Share an insight, caveat, or question.
An et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: